Agenda

Return

C. 97

To:	Board of Supervisors
From:	Anna Roth, Health Services Director
Date:	June 21, 2022

Contra

Costa

County

Subject:

Amendment to Purchase Order with POLYMEDCO, Inc. (PO #16899)

APPROVE	OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR	RECOMMENDATION OF BOARD COMMITTEE

Action of Board On: 06/21/2022

APPROVED AS RECOMMENDED

OTHER

Clerks Notes:

VOTE OF SUPERVISORS

AYE:

John Gioia, District I Supervisor
Candace Andersen, District II Supervisor
Diane Burgis, District III Supervisor
Karen Mitchoff, District IV Supervisor
Federal D. Glover, District V Supervisor

Contact:

Sam Ferrell, (925) 357-7483

I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown.
ATTESTED: June 21, 2022
Monica Nino, County Administrator

BY:	, Deputy

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Health Services Director, a purchase order amendment (PO #16899) with POLYMEDCO, Inc. to increase the payment limit by $150,000 to a new payment limit of $750,000 to procure additional reagents and supplies to perform immunochemical fecal occult blood testing for the Clinical Laboratory at Contra Costa Regional Medical Center (CCRMC), with no change to the original term of October 1, 2019 to September 30, 2022.

FISCAL IMPACT:

This action will result in additional expenditures of up to $150,000 and will be funded 100% by the Hospital Enterprise Fund I.

BACKGROUND:

Polymedco Inc.’s OC-Auto Micro 80 Analyzer with FOBT-CHECK is an automated immunochemical fecal occult blood testing system that detects human red cells only with no interferences from red meat, turnips, melons, aspirin, anti-inflammatory drugs, and vitamin C. This improvement directs many more of the “right” patients to colonoscopy leading to the earlier detection of polyps and colorectal cancer. The increased sensitivity and specifics of this test over the current method is expected to improve detection of early-stage colon cancer, which currently is the third most common cancer and the second leading cause of cancer deaths in the U.S. at 30%. The increased specificity results in fewer false positives, allowing the correct identification of those patients who need expensive colonoscopy procedures. Replacing the sigmoidoscopy and colonoscopy with this lab test for cancer screening will significantly reduce the overall cost to the organization.

Since the department has relied heavily on the utilization of the OC-Auto Micro 80 Analyzer, it is necessary to procure additional reagents and supplies to continue performing immunochemical fecal occult blood testing at the CCRMC Clinical Laboratory.

CONSEQUENCE OF NEGATIVE ACTION:

If this action is not approved, then the CCRMC Clinical Laboratory will not be able to perform neccesary patient testing for colorectal cancer.